Mitochondrial Ribosomal Protein Family in Cancers: Mechanistic Insights and Therapeutic Implications

Abstract

Mitochondria, as the main site for aerobic respiration in cells, are indispensable participants in the reprogrammed metabolic activities of tumor cells. Mitochondrial ribosomal proteins (MRPs), essential components of the mitochondrial ribosome (mitoribosome), play a critical role in maintaining mitochondrial function and regulating oncogenic signaling. Their molecular mechanisms and biological functions make MRPs key regulators of tumorigenesis, drug resistance, and tumor immune escape. MRPs are abnormally expressed in various cancer types and are linked to the prognosis of cancer patients. However, a thorough grasp of the specific mechanisms and a holistic analysis of the relationship between MRPs and different cancers are lacking. This review highlights the specific regulatory roles of MRPs, including MRPS5, MRPS29, MRPL9, MRPL12, MRPL13, MRPL33, MRPL58, and MRPL59, in cancer. Additionally, we examine the potential of MRPs as prospective clinical biomarkers and discuss their relationship with clinical prognosis and treatment response. We further explore the underlying reasons for the diverse functions of MRPs, their implications in cellular signaling and tumor immunity, and consider the prospects for developing MRP inhibitors as therapeutic strategies. Our comprehensive analysis deepens the understanding of MRPs complex biological functions and emphasizes their promising potential as therapeutic targets in cancer treatment.

Keywords

mitochondria / mitochondrial ribosomal proteins family / oxidative phosphorylation (OXPHOS) / tumorigenesis

References

[1] E. Kummer and N. Ban, “Mechanisms and Regulation of Protein Synthesis in Mitochondria,” Nature Reviews Molecular Cell Biology 22, no. 5 (2021): 307–325.

[2] G. Gopisetty and R. Thangarajan, “Mammalian Mitochondrial Ribosomal Small Subunit (MRPS) Genes: A Putative Role in Human Disease,” Gene 589, no. 1 (2016): 27–35.

[3] N. Borcherding and J. R. Brestoff, “The Power and Potential of Mitochondria Transfer,” Nature 623, no. 7986 (2023): 283–291.

[4] H. Zhang, X. Yu, J. Ye, et al., “Systematic Investigation of Mitochondrial Transfer Between Cancer Cells and T Cells at Single-Cell Resolution,” Cancer Cell 41, no. 10 (2023): 1788–1802 e10.

[5] J. G. Baldwin, C. Heuser-Loy, T. Saha, et al., “Intercellular Nanotube-Mediated Mitochondrial Transfer Enhances T Cell Metabolic Fitness and Antitumor Efficacy,” Cell 187, no. 23 (2024): 6614–6630 e21.

[6] H. Ikeda, K. Kawase, T. Nishi, et al., “Immune Evasion Through Mitochondrial Transfer in the Tumour Microenvironment,” Nature 638, no. 8049 (2025): 225–236.

[7] A. M. Storaci, I. Bertolini, C. Martelli, et al., “V-ATPase in Glioma Stem Cells: A Novel Metabolic Vulnerability,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 17.

[8] L. Sainero-Alcolado, J. Liaño-Pons, M. V. Ruiz-Pérez, and M. Arsenian-Henriksson, “Targeting Mitochondrial Metabolism for Precision Medicine in Cancer,” Cell Death & Differentiation 29, no. 7 (2022): 1304–1317.

[9] A. Pérez-González, K. Bévant, and C. Blanpain, “Cancer Cell Plasticity During Tumor Progression, Metastasis and Response to Therapy,” Nature Cancer 4, no. 8 (2023): 1063–1082.

[10] Y. Zhang, M. J. Wu, W. C. Lu, Y. C. Li, C. J. Chang, and J. Y. Yang, “Metabolic Switch Regulates Lineage Plasticity and Induces Synthetic Lethality in Triple-Negative Breast Cancer,” Cell Metabolism 36, no. 1 (2024): 193–208 e8.

[11] X. Guo, N. Yang, W. Ji, et al., “Mito-Bomb: Targeting Mitochondria for Cancer Therapy,” Advanced Materials 33, no. 43 (2021): e2007778.

[12] S. Delaunay, G. Pascual, B. Feng, et al., “Mitochondrial RNA Modifications Shape Metabolic Plasticity in Metastasis,” Nature 607, no. 7919 (2022): 593–603.

[13] W. Chen, H. Zhao, and Y. Li, “Mitochondrial Dynamics in Health and Disease: Mechanisms and Potential Targets,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 333.

[14] R. Quintana-Cabrera and L. Scorrano, “Determinants and Outcomes of Mitochondrial Dynamics,” Molecular Cell 83, no. 6 (2023): 857–876.

[15] P. S. Sridharan, Y. Koh, E. Miller, et al., “Acutely Blocking Excessive Mitochondrial Fission Prevents Chronic Neurodegeneration After Traumatic Brain Injury,” Cell Reports Medicine 5, no. 9 (2024): 101715.

[16] W. T. Dong, L. H. Long, Q. Deng, et al., “Mitochondrial Fission Drives Neuronal Metabolic Burden to Promote Stress Susceptibility in Male Mice,” Nature Metabolism 5, no. 12 (2023): 2220–2236.

[17] M. P. Murphy and L. A. J. O'Neill, “A Break in Mitochondrial Endosymbiosis as a Basis for Inflammatory Diseases,” Nature 626, no. 7998 (2024): 271–279.

[18] I. Soto, M. Couvillion, K. G. Hansen, et al., “Balanced Mitochondrial and Cytosolic Translatomes Underlie the Biogenesis of Human Respiratory Complexes,” Genome Biology 23, no. 1 (2022): 170.

[19] M. Cipullo, G. Valentín Gesé, S. Gopalakrishna, et al., “GTPBP8 Plays a Role in Mitoribosome Formation in Human Mitochondria,” Nature Communications 15, no. 1 (2024): 5664.

[20] M. Zorkau, C. A. Albus, R. Berlinguer-Palmini, Z. M. A. Chrzanowska-Lightowlers, and R. N. Lightowlers, “High-Resolution Imaging Reveals Compartmentalization of Mitochondrial Protein Synthesis in Cultured Human Cells,” Proceedings of the National Academy of Sciences 118, no. 6 (2021): e2008778118.

[21] O. Rackham and A. Filipovska, “Organization and Expression of the Mammalian Mitochondrial Genome,” Nature Reviews Genetics 23, no. 10 (2022): 606–623.

[22] B. J. Greber and N. Ban, “Structure and Function of the Mitochondrial Ribosome,” Annual Review of Biochemistry 85 (2016): 103–132.

[23] R. K. Koripella, M. R. Sharma, K. Bhargava, et al., “Structures of the Human Mitochondrial Ribosome Bound to EF-G1 Reveal Distinct Features of Mitochondrial Translation Elongation,” Nature Communications 11, no. 1 (2020): 3830.

[24] G. Huang, H. Li, and H. Zhang, “Abnormal Expression of Mitochondrial Ribosomal Proteins and Their Encoding Genes With Cell Apoptosis and Diseases,” International Journal of Molecular Sciences 21, no. 22 (2020): 8879.

[25] M. Jaskolowski, D. J. F. Ramrath, P. Bieri, et al., “Structural Insights Into the Mechanism of Mitoribosomal Large Subunit Biogenesis,” Molecular Cell 79, no. 4 (2020): 629–644 e4.

[26] E. Cavdar Koc, W. Burkhart, K. Blackburn, A. Moseley, and L. L. Spremulli, “The Small Subunit of the Mammalian Mitochondrial Ribosome. Identification of the Full Complement of Ribosomal Proteins Present,” Journal of Biological Chemistry 276, no. 22 (2001): 19363–19374.

[27] X. Li, M. Wang, S. Li, et al., “HIF-1-induced Mitochondrial Ribosome Protein L52: A Mechanism for Breast Cancer Cellular Adaptation and Metastatic Initiation in Response to Hypoxia,” Theranostics 11, no. 15 (2021): 7337–7359.

[28] T. R. Richman, J. A. Ermer, S. J. Siira, et al., “Mitochondrial Mistranslation Modulated by Metabolic Stress Causes Cardiovascular Disease and Reduced Lifespan,” Aging Cell 20, no. 7 (2021): e13408.

[29] A. Karger, S. Mansouri, M. S. Leisegang, et al., “ADPGK-AS1 Long Noncoding RNA Switches Macrophage Metabolic and Phenotypic State to Promote Lung Cancer Growth,” EMBO Journal 42, no. 18 (2023): e111620.

[30] S. Piao, I. Lee, S. Kim, et al., “CRIF1 sIRNA-Encapsulated PLGA Nanoparticles Suppress Tumor Growth in MCF-7 Human Breast Cancer Cells,” International Journal of Molecular Sciences 24, no. 8 (2023): 7453.

[31] H. J. Kim, P. Maiti, and A. Barrientos, “Mitochondrial Ribosomes in Cancer,” Seminars in Cancer Biology 47 (2017): 67–81.

[32] T. Gardeitchik, M. Mohamed, B. Ruzzenente, et al., “Bi-Allelic Mutations in the Mitochondrial Ribosomal Protein MRPS2 Cause Sensorineural Hearing Loss, Hypoglycemia, and Multiple Oxphos Complex Deficiencies,” American Journal of Human Genetics 102, no. 4 (2018): 685–695.

[33] D. Mo, C. Liu, Y. Chen, et al., “The Mitochondrial Ribosomal Protein mRpL4 Regulates Notch Signaling,” EMBO Reports 24, no. 6 (2023): e55764.

[34] A. K. Rai, S. Sanghvi, N. S. Muthukumaran, et al., “Role of Mitochondrial Ribosomal Protein L7/L12 (MRPL12) in Diabetic Ischemic Heart Disease,” Free Radical Biology and Medicine 222 (2024): 531–538.

[35] M. Uhlen, L. Fagerberg, B. M. Hallstrom, et al., “Proteomics. Tissue-Based Map of the Human Proteome,” Science 347, no. 6220 (2015): 1260419.

[36] J. L. Raynor, N. Collins, H. Shi, et al., “CRISPR Screens Unveil Nutrient-Dependent Lysosomal and Mitochondrial Nodes Impacting Intestinal Tissue-Resident Memory CD8(+) T Cell Formation,” Immunity 57, no. 11 (2024): 2597–2614.e13.

[37] F. Gao, T. Liang, Y. W. Lu, et al., “Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration,” Circulation 148, no. 23 (2023): 1887–1906.

[38] R. Akbergenov, S. Duscha, A. K. Fritz, et al., “Mutant MRPS5 Affects Mitoribosomal Accuracy and Confers Stress-Related Behavioral Alterations,” EMBO Reports 19, no. 11 (2018): e46193.

[39] Z. Wei, J. Jia, G. Heng, et al., “Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells,” Hepatology 70, no. 4 (2019): 1197–1213.

[40] L. Ali and C. M. Haynes, “Mitochondrial Translation, Dynamics, and Lysosomes Combine to Extend Lifespan,” Journal of Cell Biology 219, no. 6 (2020): e202005084.

[41] R. H. Houtkooper, L. Mouchiroud, D. Ryu, et al., “Mitonuclear Protein Imbalance as a Conserved Longevity Mechanism,” Nature 497, no. 7450 (2013): 451–457.

[42] F. Gao, T. Liang, Y. W. Lu, et al., “A Defect in Mitochondrial Protein Translation Influences Mitonuclear Communication in the Heart,” Nature Communications 14, no. 1 (2023): 1595.

[43] L. Li and B. J. Feldman, “White Adipocytes in Subcutaneous Fat Depots Require KLF15 for Maintenance in Preclinical Models,” Journal of Clinical Investigation 134, no. 13 (2024): e172360.

[44] T. Yoda, K. M. McNamara, Y. Miki, et al., “KLF15 in Breast Cancer: A Novel Tumor Suppressor?,” Cellular Oncology 38, no. 3 (2015): 227–235.

[45] X. Zhao, L. Chen, J. Wu, J. You, Q. Hong, and F. Ye, “Transcription Factor KLF15 Inhibits the Proliferation and Migration of Gastric Cancer Cells via Regulating the TFAP2A-AS1/NISCH Axis,” Biology Direct 16, no. 1 (2021): 21.

[46] G. Yang, W. Guan, Z. Cao, et al., “Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-Derived Xenograft Models,” Clinical Cancer Research 27, no. 12 (2021): 3383–3396.

[47] Z. Cheng, K. Xue, C. Xiong, Z. Zheng, J. Li, and X. Qiao, “MRPS16 Promotes Lung Adenocarcinoma Growth via the PI3K/AKT/Frataxin Signalling Axis,” Journal of Cellular and Molecular Medicine 28, no. 7 (2024): e18166.

[48] Z. Wang, J. Li, X. Long, L. Jiao, M. Zhou, and K. Wu, “MRPS16 Facilitates Tumor Progression via the PI3K/AKT/Snail Signaling Axis,” Journal of Cancer 11, no. 8 (2020): 2032–2043.

[49] M. Mushtaq, L. Kovalevska, S. Darekar, et al., “Cell Stemness Is Maintained Upon Concurrent Expression of RB and the Mitochondrial Ribosomal Protein S18-2,” Proceedings of the National Academy of Sciences 117, no. 27 (2020): 15673–15683.

[50] L. Liu, X. Zhang, H. Ding, et al., “Arginine and Lysine Methylation of MRPS23 Promotes Breast Cancer Metastasis Through Regulating Oxphos,” Oncogene 40, no. 20 (2021): 3548–3563.

[51] C. Zheng, H. Yao, L. Lu, et al., “Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-Inhibitory Effect of Lovastatin,” International Journal of Biological Sciences 20, no. 6 (2024): 2130–2148.

[52] J. Han, O. An, H. Hong, et al., “Suppression of Adenosine-to-Inosine (A-To-I) RNA Editome by Death Associated Protein 3 (DAP3) Promotes Cancer Progression,” Science Advances 6, no. 25 (2020): eaba5136.

[53] J. Han, Y. Song, J. Xie, et al., “Modulation of m(6)A RNA Modification by DAP3 in Cancer Cells,” Proceedings of the National Academy of Sciences 121, no. 40 (2024): e2404509121.

[54] J. Han, O. An, X. Ren, et al., “Multilayered Control of Splicing Regulatory Networks by DAP3 Leads to Widespread Alternative Splicing Changes in Cancer,” Nature Communications 13, no. 1 (2022): 1793.

[55] S. Tan, X. Zhang, X. Guo, et al., “DAP3 Promotes Mitochondrial Activity and Tumour Progression in Hepatocellular Carcinoma by Regulating MT-ND5 Expression,” Cell Death & Disease 15, no. 7 (2024): 540.

[56] W. Tian, Y. Tang, Y. Luo, et al., “AURKAIP1 Actuates Tumor Progression Through Stabilizing DDX5 in Triple Negative Breast Cancer,” Cell Death & Disease 14, no. 12 (2023): 790.

[57] H. M. Zhang, Z. Y. Li, Z. T. Dai, et al., “Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid Cancer,” International Journal of Molecular Sciences 23, no. 19 (2022): 11989.

[58] X. Ji, T. Zhang, J. Sun, et al., “UBASH3B-mediated MRPL12 Y60 Dephosphorylation Inhibits LUAD Development by Driving Mitochondrial Metabolism Reprogramming,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 268.

[59] Y. Zheng, S. Ye, S. Huang, et al., “Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma,” Advanced Science 11, no. 30 (2024): e2401789.

[60] X. Ji, Z. Yang, C. Li, et al., “Mitochondrial Ribosomal Protein L12 Potentiates Hepatocellular Carcinoma by Regulating Mitochondrial Biogenesis and Metabolic Reprogramming,” Metabolism: Clinical and Experimental 152 (2024): 155761.

[61] C. Jing, R. Fu, C. Wang, X. Li, and W. Zhang, “MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer,” Cancer Management and Research 13 (2021): 5535–5545.

[62] L. Liu, C. Luo, Y. Luo, et al., “MRPL33 and Its Splicing Regulator hnRNPK Are Required for Mitochondria Function and Implicated in Tumor Progression,” Oncogene 37, no. 1 (2018): 86–94.

[63] C. Lu, J. Li, D. Li, et al., “RNA-Binding Motif Protein RBM39 Enhances the Proliferation of Gastric Cancer Cells by Facilitating an Oncogenic Splicing Switch in MRPL33,” Acta Pharmacologica Sinica 46, no. 4 (2025): 1068–1081.

[64] L. Zhang, P. Lu, L. Yan, et al., “MRPL35 Is Up-Regulated in Colorectal Cancer and Regulates Colorectal Cancer Cell Growth and Apoptosis,” American Journal of Pathology 189, no. 5 (2019): 1105–1120.

[65] L. Yuan, Y. Yang, X. Li, et al., “18β-glycyrrhetinic Acid Regulates Mitochondrial Ribosomal Protein L35-Associated Apoptosis Signaling Pathways to Inhibit Proliferation of Gastric Carcinoma Cells,” World Journal of Gastroenterology 28, no. 22 (2022): 2437–2456.

[66] L. Yuan, J. X. Li, Y. Yang, et al., “Depletion of MRPL35 Inhibits Gastric Carcinoma Cell Proliferation by Regulating Downstream Signaling Proteins,” World Journal of Gastroenterology 27, no. 16 (2021): 1785–1804.

[67] W. Chang, Z. Yu, M. Tian, and X. Lin, “Immature Colon Carcinoma Transcript-1 Promotes Cell Growth of Hepatocellular Carcinoma via Facilitating Cell Cycle Progression and Apoptosis Resistance,” Oncology Reports 38, no. 6 (2017): 3489–3496.

[68] Q. Ran, F. Jin, Y. Xiang, et al., “CRIF1 as a Potential Target to Improve the Radiosensitivity of Osteosarcoma,” Proceedings of the National Academy of Sciences 116, no. 41 (2019): 20511–20516.

[69] S. Lee, S. G. Song, G. Kim, et al., “CRIF1 Deficiency Induces FOXP3(LOW) Inflammatory Non-Suppressive Regulatory T Cells, Thereby Promoting Antitumor Immunity,” Science Advances 10, no. 13 (2024): eadj9600.

[70] B. S. Song, J. S. Moon, J. Tian, et al., “Mitoribosomal Defects Aggravate Liver Cancer via Aberrant Glycolytic Flux and T Cell Exhaustion,” Journal for Immunotherapy of Cancer 10, no. 5 (2022): e004337.

[71] H. Chang, J. Li, K. Qu, et al., “CRIF1 Overexpression Facilitates Tumor Growth and Metastasis Through Inducing ROS/NFκB Pathway in Hepatocellular Carcinoma,” Cell Death & Disease 11, no. 5 (2020): 332.

[72] Y. M. Tsui, L. K. Chan, and I. O. L. Ng, “Cancer Stemness in Hepatocellular Carcinoma: Mechanisms and Translational Potential,” British Journal of Cancer 122, no. 10 (2020): 1428–1440.

[73] Y. Wu, L. Tang, H. Huang, et al., “Phosphoglycerate Dehydrogenase Activates PKM2 to Phosphorylate Histone H3T11 and Attenuate Cellular Senescence,” Nature Communications 14, no. 1 (2023): 1323.

[74] L. Sui, L. Ye, A. J. Sanders, et al., “Expression of Death Associated Proteins DAP1 and DAP3 in Human Pancreatic Cancer,” Anticancer Research 41, no. 5 (2021): 2357–2362.

[75] H. Sasaki, N. Ide, H. Yukiue, et al., “Arg and DAP3 Expression Was Correlated With Human Thymoma Stage,” Clinical & Experimental Metastasis 21, no. 6 (2004): 507–513.

[76] U. Wazir, W. G. Jiang, A. K. Sharma, and K. Mokbel, “The mRNA Expression of DAP3 in Human Breast Cancer: Correlation With Clinicopathological Parameters,” Anticancer Research 32, no. 2 (2012): 671–674.

[77] A. Kimchi, “DAP Kinase and DAP-3: Novel Positive Mediators of Apoptosis,” supplement, Annals of the Rheumatic Diseases 58, no. S1 (1999): I14–I19.

[78] J. Ramírez-Moya, A. R. Baker, F. J. Slack, and P. Santisteban, “ADAR1-Mediated RNA Editing Is a Novel Oncogenic Process in Thyroid Cancer and Regulates miR-200 Activity,” Oncogene 39, no. 18 (2020): 3738–3753.

[79] C. R. Walkley and J. B. Li, “Rewriting the Transcriptome: Adenosine-to-Inosine RNA Editing by ADARs,” Genome Biology 18, no. 1 (2017): 205.

[80] M. B. Uddin, Z. Wang, and C. Yang, “Epitranscriptomic RNA m(6)A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 4 (2024): e2403936.

[81] A. M. Maldonado López, E. K. Ko, S. Huang, et al., “Mettl3-catalyzed m(6)A Regulates Histone Modifier and Modification Expression in Self-Renewing Somatic Tissue,” Science Advances 9, no. 35 (2023): eadg5234.

[82] Y. Lu, J. Zhu, Y. Zhang, et al., “Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC,” Advanced Science 11, no. 46 (2024): e2401399.

[83] E. Villa, U. Sahu, B. P. O'Hara, et al., “mTORC1 Stimulates Cell Growth Through SAM Synthesis and m(6)A mRNA-Dependent Control of Protein Synthesis,” Molecular Cell 81, no. 10 (2021): 2076–2093.e9.

[84] J. L. Kissil, L. P. Deiss, M. Bayewitch, T. Raveh, G. Khaspekov, and A. Kimchi, “Isolation of DAP3, a Novel Mediator of Interferon-γ-Induced Cell Death,” Journal of Biological Chemistry 270, no. 46 (1995): 27932–27936.

[85] T. Miyazaki, M. Shen, D. Fujikura, et al., “Functional Role of Death-Associated Protein 3 (DAP3) in Anoikis,” Journal of Biological Chemistry 279, no. 43 (2004): 44667–44672.

[86] L. Mariani, C. Beaudry, W. S. McDonough, et al., “Death-Associated Protein 3 (Dap-3) Is Overexpressed in Invasive Glioblastoma Cells In Vivo and in Glioma Cell Lines With Induced Motility Phenotype In Vitro,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 7, no. 8 (2001): 2480–2489.

[87] M. J. Han, D. T. Chiu, and E. C. Koc, “Regulation of Mitochondrial Ribosomal Protein S29 (MRPS29) Expression by a 5'-Upstream Open Reading Frame,” Mitochondrion 10, no. 3 (2010): 274–283.

[88] T. Miyazaki and J. C. Reed, “A GTP-Binding Adapter Protein Couples Trail Receptors to Apoptosis-Inducing Proteins,” Nature Immunology 2, no. 6 (2001): 493–500.

[89] Y. Jia, L. Ye, K. Ji, et al., “Death-Associated Protein-3, DAP-3, Correlates With Preoperative Chemotherapy Effectiveness and Prognosis of Gastric Cancer Patients Following Perioperative Chemotherapy and Radical Gastrectomy,” British Journal of Cancer 110, no. 2 (2014): 421–429.

[90] J. L. Kissil, “Structure-Function Analysis of an Evolutionary Conserved Protein, DAP3, Which Mediates TNF-Alpha- and Fas-Induced Cell Death,” EMBO Journal 18, no. 2 (1999): 353–362.

[91] T. B. Smith, R. Kopajtich, L. A. M. Demain, et al., “Bi-Allelic Variants in DAP3 Result in Reduced Assembly of the Mitoribosomal Small Subunit With Altered Apoptosis and a Perrault-Syndrome-Spectrum Phenotype,” American Journal of Human Genetics 112, no. 1 (2025): 59–74.

[92] Y. Liu, Z. Cheng, Y. Pang, et al., “Role of MicroRNAas, CircRNAs and Long Noncoding RNAs in Acute Myeloid Leukemia,” Journal of Hematology & Oncology 12, no. 1 (2019): 51.

[93] X. Liu, R. Xi, X. Du, et al., “Dna Methylation of microRNA-365-1 Induces Apoptosis of Hair Follicle Stem Cells by Targeting DAP3,” Non-coding RNA Research 9, no. 3 (2024): 901–912.

[94] J. W. Zhao, W. Y. Zhao, X. H. Cui, L. Xing, J. C. Shi, and L. Yu, “The Role of the Mitochondrial Ribosomal Protein Family in Detecting Hepatocellular Carcinoma and Predicting Prognosis, Immune Features, and Drug Sensitivity,” Clinical and Translational Oncology 26, no. 2 (2024): 496–514.

[95] B. Tang, J. Zhu, Z. Zhao, et al., “Diagnosis and Prognosis Models for Hepatocellular Carcinoma Patient's Management Based on Tumor Mutation Burden,” Journal of Advanced Research 33 (2021): 153–165.

[96] R. Vishnubalaji and N. M. Alajez, “Transcriptional Landscape Associated With TNBC Resistance to Neoadjuvant Chemotherapy Revealed by Single-Cell RNA-Seq,” Molecular Therapy - Oncolytics 23 (2021): 151–162.

[97] X. Y. Li, X. Y. He, H. Zhao, L. Qi, and J. J. Lu, “Identification of a Novel Therapeutic Target for Lung Cancer: Mitochondrial Ribosome Protein L9,” Pathology - Research and Practice 248 (2023): 154625.

[98] X. Gu, Y. Liu, N. Wang, et al., “Transcription of MRPL12 Regulated by Nrf2 Contributes to the Mitochondrial Dysfunction in Diabetic Kidney Disease,” Free Radical Biology and Medicine 164 (2021): 329–340.

[99] J. Nouws, A. V. Goswami, M. Bestwick, B. J. McCann, Y. V. Surovtseva, and G. S. Shadel, “Mitochondrial Ribosomal Protein L12 Is Required for POLRMT Stability and Exists as Two Forms Generated by Alternative Proteolysis During Import,” Journal of Biological Chemistry 291, no. 2 (2016): 989–997.

[100] Y. Hu, Y. Liu, C. Ma, and K. Ai, “MRPL12 Acts as A Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung Adenocarcinoma,” International Journal of Molecular Sciences 24, no. 3 (2023): 2762.

[101] R. Zeng, E. Smith, and A. Barrientos, “Yeast Mitoribosome Large Subunit Assembly Proceeds by Hierarchical Incorporation of Protein Clusters and Modules on the Inner Membrane,” Cell Metabolism 27, no. 3 (2018): 645–656.e7.

[102] Y. Kudo, M. Sugimoto, E. Arias, et al., “PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression,” Cancer Cell 38, no. 2 (2020): 247–262.e11.

[103] C. J. Schmidlin, A. Shakya, M. Dodson, E. Chapman, and D. D. Zhang, The Intricacies of NRF2 Regulation in Cancer (Elsevier, 2021), 110–119.

[104] Y. Liu, F. Lang, and C. Yang, “NRF2 in Human Neoplasm: Cancer Biology and Potential Therapeutic Target,” Pharmacology & Therapeutics 217 (2021): 107664.

[105] Y. Sun, Q. Li, Y. Huang, et al., “Natural Products for Enhancing the Sensitivity or Decreasing the Adverse Effects of Anticancer Drugs Through Regulating the Redox Balance,” Chinese Medicine 19, no. 1 (2024): 110.

[106] H. Wang, P. Concannon, and Y. Ge, “Roles of TULA-Family Proteins in T Cells and Autoimmune Diseases,” Genes & Immunity 26, no. 1 (2025): 54–62.

[107] Z. Tao, H. Suo, L. Zhang, et al., “MRPL13 Is a Prognostic Cancer Biomarker and Correlates With Immune Infiltrates in Breast Cancer,” Oncotargets Ther 13 (2020): 12255–12268.

[108] X. Zhong, Z. He, Y. Fan, et al., “Multi-Omics Analysis of MRPL-13 as a Tumor-Promoting Marker From Pan-Cancer to Lung Adenocarcinoma,” Aging 15, no. 19 (2023): 10640–10680.

[109] M. Cai, H. Li, R. Chen, and X. Zhou, “MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway,” Cancer Management and Research 13 (2021): 2009–2024.

[110] W. Zhang, G. Wang, Z. G. Xu, et al., “Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVs,” Cell 178, no. 1 (2019): 176–189 e15.

[111] M. Logozzi, E. Spugnini, D. Mizzoni, R. Di Raimo, and S. Fais, “Extracellular Acidity and Increased Exosome Release as Key Phenotypes of Malignant Tumors,” Cancer and Metastasis Reviews 38, no. 1/2 (2019): 93–101.

[112] Y. K. Lee, J. J. Lim, U. Jeoun, et al., “Lactate-Mediated Mitoribosomal Defects Impair Mitochondrial Oxidative Phosphorylation and Promote Hepatoma Cell Invasiveness,” Journal of Biological Chemistry 292, no. 49 (2017): 20208–20217.

[113] R. Qiu, H. Shi, S. Wang, et al., “BRMS1 Coordinates With LSD1 and Suppresses Breast Cancer Cell Metastasis,” American Journal of Cancer Research 8, no. 10 (2018): 2030–2045.

[114] J. Li, D. Feng, C. Gao, et al., “Isoforms S and L of MRPL33 From Alternative Splicing Have Isoform‑Specific Roles in the Chemoresponse to Epirubicin in Gastric Cancer Cells via the PI3K/AKT Signaling Pathway,” International Journal of Oncology 54, no. 5 (2019): 1591–1600.

[115] M. L. You, Y. J. Chen, Q. Y. Chong, et al., “Trefoil Factor 3 Mediation of Oncogenicity and Chemoresistance in Hepatocellular Carcinoma Is AKT-BCL-2 Dependent,” Oncotarget 8, no. 24 (2017): 39323–39344.

[116] H. Li, X. Shen, M. Ma, et al., “ZIP10 Drives Osteosarcoma Proliferation and Chemoresistance Through ITGA10-Mediated Activation of the PI3K/AKT Pathway,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 340.

[117] B. Mucha, S. Qie, S. Bajpai, et al., “Tumor Suppressor Mediated Ubiquitylation of hnRNPK Is a Barrier to Oncogenic Translation,” Nature Communications 13, no. 1 (2022): 6614.

[118] N. van Belzen, M. P. G. Diesveld, A. C. J. van der Made, et al., “Identification of mRNAs That Show Modulated Expression During Colon Carcinoma Cell Differentiation,” European Journal of Biochemistry 234, no. 3 (1995): 843–848.

[119] M. E. Haque and L. L. Spremulli, “ICT1 Comes to the Rescue of Mitochondrial Ribosomes,” EMBO Journal 29, no. 6 (2010): 1019–1020.

[120] R. Richter, J. Rorbach, A. Pajak, et al., “A Functional Peptidyl-tRNA Hydrolase, ICT1, Has Been Recruited Into the Human Mitochondrial Ribosome,” EMBO Journal 29, no. 6 (2010): 1116–1125.

[121] S. Akabane, T. Ueda, K. H. Nierhaus, and N. Takeuchi, “Ribosome Rescue and Translation Termination at Non-Standard Stop Codons by ICT1 in Mammalian Mitochondria,” PLoS Genetics 10, no. 9 (2014): e1004616.

[122] Y. Tao, Y. Song, T. Han, C. Wang, T. Zhao, and Y. Gu, “miR-205 Regulation of ICT1 Has an Oncogenic Potential via Promoting the Migration and Invasion of Gastric Cancer Cells,” Biomedicine & Pharmacotherapy 96 (2017): 191–197.

[123] C. Wang, C. Liang, W. Feng, et al., “ICT1 Knockdown Inhibits Breast Cancer Cell Growth via Induction of Cell Cycle Arrest and Apoptosis,” International Journal of Molecular Medicine 39, no. 4 (2017): 1037–1045.

[124] G. Y. Li, J. Z. Liu, L. Zhang, et al., “Knockdown of Immature Colon Carcinoma Transcript 1 Induces Suppression of Proliferation, S-Phase Arrest and Apoptosis in Leukemia Cells,” Oncology Reports 39, no. 3 (2018): 1269–1275.

[125] X. Peng, B. Yan, and Y. Shen, “MiR-1301-3p Inhibits Human Breast Cancer Cell Proliferation by Regulating Cell Cycle Progression and Apoptosis Through Directly Targeting ICT1,” Breast Cancer 25, no. 6 (2018): 742–752.

[126] H. K. Chung, Y. W. Yi, N. C. Jung, et al., “CR6-interacting Factor 1 Interacts With Gadd45 Family Proteins and Modulates the Cell Cycle,” Journal of Biological Chemistry 278, no. 30 (2003): 28079–28088.

[127] E. C. Koc, H. Cimen, B. Kumcuoglu, et al., “Identification and Characterization of CHCHD1, AURKAIP1, and CRIF1 as New Members of the Mammalian Mitochondrial Ribosome,” Frontiers in Physiology 4 (2013): 183.

[128] H. G. Colaço, A. Barros, A. Neves-Costa, et al., “Tetracycline Antibiotics Induce Host-Dependent Disease Tolerance to Infection,” Immunity 54, no. 1 (2021): 53–67 e7.

[129] G. M. Kang, S. H. Min, C. H. Lee, et al., “Mitohormesis in Hypothalamic POMC Neurons Mediates Regular Exercise-Induced High-Turnover Metabolism,” Cell Metabolism 33, no. 2 (2021): 334–349 e6.

[130] H. J. Hong, K. H. Joung, Y. K. Kim, et al., “Mitoribosome Insufficiency in β Cells Is Associated With Type 2 Diabetes-Like Islet Failure,” Experimental & Molecular Medicine 54, no. 7 (2022): 932–945.

[131] M. J. Choi, S. B. Jung, S. E. Lee, et al., “An Adipocyte-Specific Defect in Oxidative Phosphorylation Increases Systemic Energy Expenditure and Protects Against Diet-Induced Obesity in Mouse Models,” Diabetologia 63, no. 4 (2020): 837–852.

[132] J. Y. Heo, A. H. Park, M. J. Lee, et al., “Crif1 Deficiency in Dopamine Neurons Triggers Early-Onset Parkinsonism,” Molecular Psychiatry 28, no. 10 (2023): 4474–4484.

[133] S. Kim, S. Piao, I. Lee, et al., “CR6 Interacting Factor 1 Deficiency Induces Premature Senescence via SIRT3 Inhibition in Endothelial Cells,” Free Radical Biology and Medicine 150 (2020): 161–171.

[134] J. S. Park, S. Yang, S. H. Hwang, et al., “B Cell-Specific Deletion of CR6-Interacting Factor 1 Drives Lupus-Like Autoimmunity by Activation of Interleukin-17, Interleukin-6, and Pathogenic Follicular Helper T Cells in a Mouse Model,” Arthritis & Rheumatology 74, no. 7 (2022): 1211–1222.

[135] L. X. Xiang, Q. Ran, L. Chen, et al., “CR6-Interacting Factor-1 Contributes to Osteoclastogenesis by Inducing Receptor Activator of Nuclear Factor κB Ligand After Radiation,” World Journal of Stem Cells 12, no. 3 (2020): 222–240.

[136] S. J. Kim, M. Kwon, M. J. Ryu, et al., “CRIF1 Is Essential for the Synthesis and Insertion of Oxidative Phosphorylation Polypeptides in the Mammalian Mitochondrial Membrane,” Cell Metabolism 16, no. 2 (2012): 274–283.

[137] Y. Xiong, M. Wang, J. Zhao, et al., “SIRT3 Is Correlated With the Malignancy of Non-Small Cell Lung Cancer,” International Journal of Oncology 50, no. 3 (2017): 903–910.

[138] Q. Wang, Z. Xie, C. Li, et al., “CRIF1 Promotes the Progression of Non-Small-Cell Lung Cancer by SIRT3- Mediated Deacetylation of PYCR1,” Journal of Molecular Histology 53, no. 4 (2022): 657–667.

[139] E. J. Kay, K. Paterson, C. Riera-Domingo, et al., “Cancer-Associated Fibroblasts Require Proline Synthesis by PYCR1 for the Deposition of Pro-Tumorigenic Extracellular Matrix,” Nature Metabolism 4, no. 6 (2022): 693–710.

[140] Q. Ran, Y. Xiang, P. Stephen, et al., “CRIF1-CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity,” Journal of the American Chemical Society 141, no. 4 (2019): 1420–1424.

[141] K. Wang and J. E. Tepper, “Radiation Therapy-Associated Toxicity: Etiology, Management, and Prevention,” CA: A Cancer Journal for Clinicians 71, no. 5 (2021): 437–454.

[142] Y. Liu, T. He, Z. Li, et al., “TET2 Is Recruited by CREB to Promote Cebpb, Cebpa, and Pparg Transcription by Facilitating Hydroxymethylation During Adipocyte Differentiation,” Iscience 26, no. 11 (2023): 108312.

[143] X. Zhang, L. Xiang, Q. Ran, et al., “Crif1 Promotes Adipogenic Differentiation of Bone Marrow Mesenchymal Stem Cells After Irradiation by Modulating the PKA/CREB Signaling Pathway,” Stem Cells 33, no. 6 (2015): 1915–1926.

[144] L. Chen, Q. Ran, Y. Xiang, et al., “Co-Activation of PKC-δ by CRIF1 Modulates Oxidative Stress in Bone Marrow Multipotent Mesenchymal Stromal Cells After Irradiation by Phosphorylating NRF2 Ser40,” Theranostics 7, no. 10 (2017): 2634–2648.

[145] M. Rao, S. Xu, Y. Zhang, Y. Liu, W. Luan, and J. Zhou, “Long Non-Coding RNA ZFAS1 Promotes Pancreatic Cancer Proliferation and Metastasis by Sponging miR-497-5p to Regulate HMGA2 Expression,” Cell Death & Disease 12, no. 10 (2021): 859.

[146] T. Saito, H. Nishikawa, H. Wada, et al., “Two FOXP3(+)CD4(+) T Cell Subpopulations Distinctly Control the Prognosis of Colorectal Cancers,” Nature Medicine 22, no. 6 (2016): 679–684.

[147] C. A. Klein, “Cancer Progression and the Invisible Phase of Metastatic Colonization,” Nature Reviews Cancer 20, no. 11 (2020): 681–694.

[148] R. M. Memmott, A. R. Wolfe, D. P. Carbone, and T. M. Williams, “Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors,” Journal of Thoracic Oncology 16, no. 7 (2021): 1086–1098.

[149] S. G. Kisling, P. Atri, A. Shah, et al., “A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-Term Survivors of Pancreatic Ductal Adenocarcinoma,” Clinical Cancer Research 29, no. 18 (2023): 3759–3770.

[150] M. Karlsson, C. Zhang, L. Méar, et al., “A Single-Cell Type Transcriptomics Map of Human Tissues,” Science Advances 7, no. 31 (2021): eabh2169.

[151] S. Zhang, H. Guo, H. Wang, et al., “A Novel Mitochondrial Unfolded Protein Response-Related Risk Signature to Predict Prognosis, Immunotherapy and Sorafenib Sensitivity in Hepatocellular Carcinoma,” Apoptosis 29, no. 5/6 (2024): 768–784.

[152] S. Min, Y. K. Lee, J. Hong, et al., “MRPS31 Loss Is a Key Driver of Mitochondrial Deregulation and Hepatocellular Carcinoma Aggressiveness,” Cell Death & Disease 12, no. 11 (2021): 1076.

[153] C. Yang, H. Zhang, L. Zhang, et al., “Evolving Therapeutic Landscape of Advanced Hepatocellular Carcinoma,” Nature Reviews Gastroenterology & Hepatology 20, no. 4 (2023): 203–222.

[154] D. L. Gu, “Target Genes Discovery Through Copy Number Alteration Analysis in Human Hepatocellular Carcinoma,” World Journal of Gastroenterology 19, no. 47 (2013): 8873–8879.

[155] B. A. Jee, J. H. Choi, H. Rhee, et al., “Dynamics of Genomic, Epigenomic, and Transcriptomic Aberrations During Stepwise Hepatocarcinogenesis,” Cancer Research 79, no. 21 (2019): 5500–5512.

[156] L. Kraehenbuehl, C. H. Weng, S. Eghbali, J. D. Wolchok, and T. Merghoub, “Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways,” Nature Reviews Clinical Oncology 19, no. 1 (2022): 37–50.

[157] Z. Tang, M. C. Zhong, J. Qian, et al., “CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity,” Nature Immunology 24, no. 12 (2023): 2032–2041.

[158] Z. Tang, D. Davidson, R. Li, et al., “Inflammatory Macrophages Exploit Unconventional Pro-Phagocytic Integrins for Phagocytosis and Anti-Tumor Immunity,” Cell Reports 37, no. 11 (2021): 110111.

[159] S. T. Paijens, A. Vledder, M. de Bruyn, and H. W. Nijman, “Tumor-Infiltrating Lymphocytes in the Immunotherapy Era,” Cellular & Molecular Immunology 18, no. 4 (2021): 842–859.

[160] P. Apostolova and E. L. Pearce, “Lactic Acid and Lactate: Revisiting the Physiological Roles in the Tumor Microenvironment,” Trends in Immunology 43, no. 12 (2022): 969–977.

[161] R. Bai and J. Cui, “Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria,” Cancer Letters 564 (2023): 216223.

[162] X. Li, Y. Yang, B. Zhang, et al., “Lactate Metabolism in Human Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 305.

[163] E. N. Arner and J. C. Rathmell, “Metabolic Programming and Immune Suppression in the Tumor Microenvironment,” Cancer Cell 41, no. 3 (2023): 421–433.

[164] L. Ye, Y. Jiang, and M. Zhang, “Crosstalk Between Glucose Metabolism, Lactate Production and Immune Response Modulation,” Cytokine & Growth Factor Reviews 68 (2022): 81–92.

[165] M. Certo, C. H. Tsai, V. Pucino, P. C. Ho, and C. Mauro, “Lactate Modulation of Immune Responses in Inflammatory Versus Tumour Microenvironments,” Nature Reviews Immunology 21, no. 3 (2021): 151–161.

[166] D. Chen, I. Nemazanyy, O. Peulen, et al., “Elp3-Mediated Codon-Dependent Translation Promotes mTORC2 Activation and Regulates Macrophage Polarization,” EMBO Journal 41, no. 18 (2022): e109353.

[167] Z. Liu, L. Liu, S. Weng, et al., “Best: A Web Application for Comprehensive Biomarker Exploration on Large-Scale Data in Solid Tumors,” Journal of Big Data 10, no. 1 (2023): 165.

[168] H. Zhang, L. Liu, J. Liu, et al., “Roles of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Solid Cancers,” Molecular Cancer 22, no. 1 (2023): 58.

[169] Z. H. Ye, W. B. Yu, M. Y. Huang, J. Chen, and J. J. Lu, “Building on the Backbone of CD47-Based Therapy in Cancer: Combination Strategies, Mechanisms, and Future Perspectives,” Acta Pharmaceutica Sinica B 13, no. 4 (2023): 1467–1487.

[170] M. Y. Huang, Y. C. Chen, W. Y. Lyu, et al., “Ginsenoside Rh2 Augmented Anti-PD-L1 Immunotherapy by Reinvigorating CD8(+) T Cells via Increasing Intratumoral CXCl10,” Pharmacological Research 198 (2023): 106988.

[171] X. Zhang, D. Tang, H. Xiao, B. Li, K. Shang, and D. Zhao, “Activating the cGAS-STING Pathway by Manganese-Based Nanoparticles Combined With Platinum-Based Nanoparticles for Enhanced Ovarian Cancer Immunotherapy,” ACS Nano 19, no. 4 (2025): 4346–4365.

[172] L. Pei, Y. Liu, L. Liu, et al., “Roles of Cancer-Associated Fibroblasts (CAFs) in Anti- PD-1/PD-L1 Immunotherapy for Solid Cancers,” Molecular Cancer 22, no. 1 (2023): 29.

[173] Z. H. Wang, W. B. Peng, P. Zhang, X. P. Yang, and Q. Zhou, “Lactate in the Tumour Microenvironment: From Immune Modulation to Therapy,” EBioMedicine 73 (2021): 103627.

[174] C. Hayes, C. L. Donohoe, M. Davern, and N. E. Donlon, “The Oncogenic and Clinical Implications of Lactate Induced Immunosuppression in the Tumour Microenvironment,” Cancer Letters 500 (2021): 75–86.

[175] T. Li, M. Huang, and J. Lu, “Cancer Statistics and Trends in China: The Potential of Natural Product Application,” Chinese Journal of Natural Medicines 22, no. 8 (2024): 673–675.

[176] S. Chen, Z. Cao, K. Prettner, et al., “Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050,” JAMA Oncology 9, no. 4 (2023): 465–472.

[177] M. Molenaars, G. E. Janssens, E. G. Williams, et al., “A Conserved Mito-Cytosolic Translational Balance Links Two Longevity Pathways,” Cell Metabolism 31, no. 3 (2020): 549–563 e7.

[178] Y. Zong, H. Li, P. Liao, et al., “Mitochondrial Dysfunction: Mechanisms and Advances in Therapy,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 124.

[179] M. Lu, W. Li, J. Zhou, et al., “Integrative Bioinformatics Analysis for Identifying the Mitochondrial-Related Gene Signature Associated With Immune Infiltration in Premature Ovarian Insufficiency,” BMC Medicine 22, no. 1 (2024): 444.

[180] D. Sengupta, M. Deb, S. Kar, et al., “Dissecting miRNA Facilitated Physiology and Function in Human Breast Cancer for Therapeutic Intervention,” Seminars in Cancer Biology 72, no. 1096/3650 (Electronic) (2021): 46–64.

[181] X. He, G. Li, L. Huang, et al., “Nonviral Targeted mRNA Delivery: Principles, Progresses, and Challenges,” MedComm 6, no. 1 (2025): e70035.

[182] J. Lu, T. Wu, B. Zhang, et al., “Types of Nuclear Localization Signals and Mechanisms of Protein Import Into the Nucleus,” Cell Communication and Signaling 19, no. 1 (2021): 60.

[183] J. M. Lee, H. M. Hammarén, M. M. Savitski, and S. H. Baek, “Control of Protein Stability by Post-Translational Modifications,” Nature Communications 14, no. 1 (2023): 201.

[184] R. Liu, X. Ren, Y. E. Park, et al., “Nuclear GTPSCS Functions as a Lactyl-CoA Synthetase to Promote Histone Lactylation and Gliomagenesis,” Cell Metabolism 37, no. 2 (2025): 377–394 e9.

[185] W. Du, S. Tan, Y. Peng, et al., “Histone Lactylation-Driven YTHDC1 Promotes Hepatocellular Carcinoma Progression via Lipid Metabolism Remodeling,” Cancer Letters 611 (2024): 217426.

[186] H. Hong, H. Han, L. Wang, et al., “ABCF1-K430-Lactylation Promotes HCC Malignant Progression via Transcriptional Activation of HIF1 Signaling Pathway,” Cell Death & Differentiation 32, no. 4 (2025): 613–631.

[187] Y. Sato, H. Yoshino, I. Kashiwakura, and E. Tsuruga, “DAP3 Is Involved in Modulation of Cellular Radiation Response by RIG-I-Like Receptor Agonist in Human Lung Adenocarcinoma Cells,” International Journal of Molecular Sciences 22, no. 1 (2021): 420.

[188] X. Lao, Q. Feng, G. He, et al., “Immature Colon Carcinoma Transcript-1 (ICT1) Expression Correlates With Unfavorable Prognosis and Survival in Patients With Colorectal Cancer,” Annals of Surgical Oncology 23, no. 12 (2016): 3924–3933.

[189] H. Yan, Y. Zhang, Y. Zhang, et al., “CRIF1 Enhances p53 Activity via the Chromatin Remodeler SNF5 in the HCT116 Colon Cancer Cell Lines,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1860, no. 4 (2017): 516–522.

[190] Q. Ran, P. Hao, Y. Xiao, et al., “CRIF1 Interacting With CDK2 Regulates Bone Marrow Microenvironment-Induced G0/G1 Arrest of Leukemia Cells,” PLoS One 9, no. 2 (2014): e85328.

[191] Z. Mirza and S. Karim, “Nanoparticles-Based Drug Delivery and Gene Therapy for Breast Cancer: Recent Advancements and Future Challenges,” Seminars in Cancer Biology 69 (2021): 226–237.

[192] B. Kim, J. H. Park, and M. J. Sailor, “Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery,” Advanced Materials 31, no. 49 (2019): e1903637.

[193] J. Gao, S. Gunasekar, Z. Xia, et al., “Gene Therapy for CNS Disorders: Modalities, Delivery and Translational Challenges,” Nature Reviews Neuroscience 25, no. 8 (2024): 553–572.

[194] R. Luo, H. Le, Q. Wu, and C. Gong, “Nanoplatform-Based In Vivo Gene Delivery Systems for Cancer Therapy,” Small 20, no. 30 (2024): e2312153.

[195] R. H. Rouce and M. H. Porteus, “Cell and Gene Therapy Accessibility,” Science 385, no. 6708 (2024): 475.

[196] S. S. Liew, X. Qin, J. Zhou, L. Li, W. Huang, and S. Q. Yao, “Smart Design of Nanomaterials for Mitochondria-Targeted Nanotherapeutics,” Angewandte Chemie International Edition 60, no. 5 (2021): 2232–2256.

[197] K. Rajendran, A. Karthikeyan, and U. M. Krishnan, “Emerging Trends in Nano-Bioactive-Mediated Mitochondria-Targeted Therapeutic Stratagems Using Polysaccharides, Proteins and Lipidic Carriers,” International Journal of Biological Macromolecules 208, no. 1879/0003 (Electronic) (2022): 627–641.

[198] X. Li and Y. Song, “Proteolysis-Targeting Chimera (PROTAC) for Targeted Protein Degradation and Cancer Therapy,” Journal of Hematology & Oncology 13, no. 1 (2020): 50.

[199] M. M. Noblejas-López, C. Nieto-Jimenez, M. Burgos, et al., “Activity of BET-Proteolysis Targeting Chimeric (PROTAC) Compounds in Triple Negative Breast Cancer,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 383.

[200] P. P. Chamberlain and L. G. Hamann, “Development of Targeted Protein Degradation Therapeutics,” Nature Chemical Biology 15, no. 10 (2019): 937–944.

[201] T. A. Nguyen, T. F. Gronauer, T. Nast-Kolb, S. A. Sieber, and K. Lang, “Substrate Profiling of Mitochondrial Caseinolytic Protease P via a Site-Specific Photocrosslinking Approach,” Angewandte Chemie International Edition 61, no. 10 (2022): e202111085.

[202] H. Xu, Z. Jia, F. Liu, et al., “Biomarkers and Experimental Models for Cancer Immunology Investigation,” MedComm 4, no. 6 (2023): e437.

[203] P. Kjer-Hansen, T. G. Phan, and R. J. Weatheritt, “Protein Isoform-Centric Therapeutics: Expanding Targets and Increasing Specificity,” Nature Reviews Drug Discovery 23, no. 10 (2024): 759–779.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).